Metabolic-Associated Fatty Liver Disease and Sarcopenia

Triada Bali; Lampros Chrysavgis; Evangelos Cholongitas

doi:10.1016/j.ecl.2023.02.004

Metabolic-Associated Fatty Liver Disease and Sarcopenia

Endocrinol Metab Clin North Am. 2023 Sep;52(3):497-508. doi: 10.1016/j.ecl.2023.02.004. Epub 2023 Mar 15.

Authors

Triada Bali¹, Lampros Chrysavgis¹, Evangelos Cholongitas²

Affiliations

¹ First Department of Internal Medicine, General Hospital of Athens "Laiko", Medical School of National and Kapodistrian University of Athens, 17 Agiou Thoma Street, Athens 11527, Greece.
² First Department of Internal Medicine, General Hospital of Athens "Laiko", Medical School of National and Kapodistrian University of Athens, 17 Agiou Thoma Street, Athens 11527, Greece. Electronic address: cholongitas@yahoo.gr.

PMID: 37495340
DOI: 10.1016/j.ecl.2023.02.004

Abstract

The current evidence indicates a strong association between sarcopenia, the loss of muscle mass and strength, and metabolic-associated fatty liver disease (MAFLD). The two entities share many common pathophysiologic mechanisms, and their coexistence may result in higher rates of morbidity and mortality. Therefore, given their increasing incidence in the modern world, there is a need for a better understanding of the liver-muscle axis for early identification of sarcopenia in patients with MAFLD and vice versa. This review aims at presenting current data regarding the correlation between sarcopenia and MAFLD, the associated comorbidities, and the need for effective therapies.

Keywords: Diet; Insulin resistance; MAFLD; Physical activity; Sarcopenia; Sarcopenic obesity.

Publication types

Review

MeSH terms

Humans
Non-alcoholic Fatty Liver Disease* / complications
Obesity / complications
Risk Assessment
Sarcopenia* / complications
Sarcopenia* / epidemiology